Literature DB >> 11006608

Quantitation of simvastatin and its beta-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry.

J J Zhao1, I H Xie, A Y Yang, B A Roadcap, J D Rogers.   

Abstract

A sensitive and reliable procedure for the simultaneous determination of simvastatin (SV) and its active beta-hydroxy acid metabolite (SVA) in human plasma was developed and validated. The analytes were extracted simultaneously from 0.5 ml aliquots of human plasma samples by methyl tert-butyl ether (MTBE) via Chem Elut cartridge extraction [also called liquid-solid extraction (LSE) or liquid-liquid cartridge extraction (LLCE)], separated through a Kromasil C(18) column (50 x 2 mm i.d. 5 microm) and detected by tandem mass spectrometry with a turbo ionspray interface. Stable isotope-labeled SV and SVA, (13)CD(3)-SV and (13)CD(3)-SVA, were used as internal standards. SV and SVA were detected in positive and negative ion modes, respectively, via within-run polarity switching. The use of Chem Elut cartridges not only provided a simple and efficient means of plasma sample extraction but also successfully reduced the interconversion between SV and SVA to an undetectable (for lactonization of SVA) or negligible (<0.07%, for hydrolysis of SV) level. The method showed excellent reproducibility, with intra- and inter-assay precisions <4.5% (RSD), and intra- and inter-assay accuracy between 94% and 107% of nominal values, for both analytes. The extraction recoveries were 78% and 87% on average for SV and SVA, respectively. The analyte was found to be stable in plasma through three freeze (-70 degrees C)-thaw (4 degrees C) cycles and for at least 3 h under bench-top storage condition in an ice-bath (4 degrees C), and also in the reconstitution solution at 4 degrees C for at least 24 h. The method has a lower limit of quantitation (LOQ) of 50 pg ml(-1) with a linear calibration range of 0.05-50 ng ml(-1) for both analytes, and has proved to be very reliable for the analysis of clinical samples. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006608     DOI: 10.1002/1096-9888(200009)35:9<1133::AID-JMS42>3.0.CO;2-X

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  13 in total

1.  Theoretical study of hydrogen bond interactions of fluvastatin with ι-carrageenan and λ-carrageenan.

Authors:  Anastasios G Papadopoulos; Michael P Sigalas
Journal:  J Mol Model       Date:  2010-10-28       Impact factor: 1.810

2.  No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.

Authors:  Jenni E Keskitalo; Kaisa J Kurkinen; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

3.  A Simple Protein Precipitation-based Simultaneous Quantification of Lovastatin and Its Active Metabolite Lovastatin Acid in Human Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry using Polarity Switching.

Authors:  Ju Wujian; Peng Kuan-Wei; Yang Sihyung; Sun Huijing; Sampson Mario; Wang Michael Zhuo
Journal:  J Chromatogr Sep Tech       Date:  2015-05

4.  Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.

Authors:  Jasmine A Luzum; Elizabeth Theusch; Kent D Taylor; Ann Wang; Wolfgang Sadee; Philip F Binkley; Ronald M Krauss; Marisa W Medina; Joseph P Kitzmiller
Journal:  J Cardiovasc Pharmacol       Date:  2015-07       Impact factor: 3.105

5.  Enteric microbiome metabolites correlate with response to simvastatin treatment.

Authors:  Rima Kaddurah-Daouk; Rebecca A Baillie; Hongjie Zhu; Zhao-Bang Zeng; Michelle M Wiest; Uyen Thao Nguyen; Katie Wojnoonski; Steven M Watkins; Miles Trupp; Ronald M Krauss
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

6.  Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin.

Authors:  Lara M Mangravite; Marisa Wong Medina; Jinrui Cui; Sheila Pressman; Joshua D Smith; Mark J Rieder; Xiuqing Guo; Deborah A Nickerson; Jerome I Rotter; Ronald M Krauss
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-04-22       Impact factor: 8.311

7.  Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms.

Authors:  Marija Tubic-Grozdanis; John M Hilfinger; Gordon L Amidon; Jae Seung Kim; Paul Kijek; Petra Staubach; Peter Langguth
Journal:  Pharm Res       Date:  2008-01-24       Impact factor: 4.200

8.  Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers.

Authors:  Murali Shyamsundar; Scott T W McKeown; Cecilia M O'Kane; Thelma R Craig; Vanessa Brown; David R Thickett; Michael A Matthay; Clifford C Taggart; Janne T Backman; J Stuart Elborn; Daniel F McAuley
Journal:  Am J Respir Crit Care Med       Date:  2009-03-26       Impact factor: 21.405

9.  Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation.

Authors:  Stephen R Spindler; Rui Li; Joseph M Dhahbi; Amy Yamakawa; Patricia Mote; Rolf Bodmer; Karen Ocorr; Renee T Williams; Yinsheng Wang; Kenneth P Ablao
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

10.  CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.

Authors:  Joseph P Kitzmiller; Jasmine A Luzum; Damiano Baldassarre; Ronald M Krauss; Marisa W Medina
Journal:  Pharmacogenet Genomics       Date:  2014-10       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.